Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease

被引:2
作者
Henningsen, Jo B. [1 ,3 ]
Soylu-Kucharz, Rana [1 ,2 ]
Bjorkqvist, Maria [2 ]
Petersen, Asa [1 ]
机构
[1] Lund Univ, Dept Expt Med Sci, Translat Neuroendocrine Res Unit, S-22184 Lund, Sweden
[2] Lund Univ, Dept Expt Med Sci, Brain Dis Biomarker Unit, S-22184 Lund, Sweden
[3] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark
基金
瑞典研究理事会;
关键词
CART; Excitotoxicity; Huntington's disease; Hypothalamus; MCH; Orexin; Oxytocin; Quinolinic acid; TH; Vasopressin; MELANIN-CONCENTRATING HORMONE; QUINOLINIC ACID; MUTANT HUNTINGTIN; OREXIN NEURONS; SELECTIVE LOSS; MICE; LESIONS; SUSCEPTIBILITY; SENSITIVITY; EXPRESSION;
D O I
10.1016/j.heliyon.2021.e07808
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Huntington disease (HD) is a fatal neurodegenerative movement disorder caused by an expanded CAG repeat in the huntingtin gene (HTT). The mutant huntingtin protein is ubiquitously expressed, but only certain brain regions are affected. The hypothalamus has emerged as an important area of pathology with selective loss of neurons expressing the neuropeptides orexin (hypocretin), oxytocin and vasopressin in human postmortem HD tissue. Hypothalamic changes in HD may have implications for early disease manifestations affecting the regulation of sleep, emotions and metabolism. The underlying mechanisms of selective vulnerability of certain neurons in HD are not fully understood, but excitotoxicity has been proposed to play a role. Further understanding of mechanisms rendering neurons sensitive to mutant huntingtin may reveal novel targets for therapeutic interventions. In the present study, we wanted to examine whether transgenic HD mice display altered sensitivity to excitotoxicity in the hypothalamus. We first assessed effects of hypothalamic injections of the excitotoxin quinolinic acid (QA) into wild-type (WT) mice. We show that neuronal populations expressing melanin-concentrating hormone (MCH) and cocaine and amphetamine-regulated transcript (CART) display a dose-dependent sensitivity to QA. In contrast, neuronal populations expressing orexin, oxytocin, vasopressin as well as tyrosine hydroxylase in the A13 area are resistant to QA-induced toxicity. We demonstrate that the R6/2 transgenic mouse model expressing a short fragment of mutant HTT displays hypothalamic neuropathology with discrete loss of the neuronal populations expressing orexin, MCH, CART, and orexin at 12 weeks of age. The BACHD mouse model expressing full-length mutant HTT does not display any hypothalamic neuropathology at 2 months of age. There was no effect of hypothalamic injections of QA on the neuronal populations expressing orexin, MCH, CART or oxytocin in neither HD mouse model. In conclusion, we find no support for a role of excitotoxicity in the loss of hypothalamic neuronal populations in HD.
引用
收藏
页数:9
相关论文
共 33 条
[1]   Hypocretin and melanin-concentrating hormone in patients with Huntington disease [J].
Aziz, Ahmad ;
Fronczek, Rolf ;
Maat-Schieman, Marion ;
Unmehopa, Unga ;
Roelandse, Freek ;
Overeem, Sebastiaan ;
van Duinen, Sjoerd ;
Lammers, Gert-Jan ;
Swaab, Dick ;
Roos, Raymund .
BRAIN PATHOLOGY, 2008, 18 (04) :474-483
[2]   SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease [J].
Baldo, B. ;
Gabery, S. ;
Soylu-Kucharz, R. ;
Cheong, R. Y. ;
Henningsen, J. B. ;
Englund, E. ;
McLean, C. ;
Kirik, D. ;
Halliday, G. ;
Petersen, A. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2019, 45 (04) :361-379
[3]  
BEAL MF, 1991, J NEUROSCI, V11, P1649
[4]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[5]   Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists [J].
Behan, WMH ;
Stone, TW .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (06) :1435-1442
[6]   Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease [J].
Björkqvist, M ;
Petersén, Å ;
Bacos, K ;
Isaacs, J ;
Norlén, P ;
Gil, J ;
Popovic, N ;
Sundler, F ;
Bates, GP ;
Tabrizi, SJ ;
Brundin, P ;
Mulder, H .
HUMAN MOLECULAR GENETICS, 2006, 15 (10) :1713-1721
[7]   The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease [J].
Cheong, Rachel Y. ;
Gabery, Sanaz ;
Petersen, Asa .
JOURNAL OF HUNTINGTONS DISEASE, 2019, 8 (04) :375-391
[8]   EXCITOTOXIN LESIONS IN PRIMATES AS A MODEL FOR HUNTINGTONS-DISEASE - HISTOPATHOLOGIC AND NEUROCHEMICAL CHARACTERIZATION [J].
FERRANTE, RJ ;
KOWALL, NW ;
CIPOLLONI, PB ;
STOREY, E ;
BEAL, MF .
EXPERIMENTAL NEUROLOGY, 1993, 119 (01) :46-71
[9]   Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study [J].
Gabery, S. ;
Halliday, G. ;
Kirik, D. ;
Englund, E. ;
Petersen, A. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2015, 41 (06) :843-848
[10]   Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses [J].
Gabery, Sanaz ;
Murphy, Karen ;
Schultz, Kristofer ;
Loy, Clement T. ;
McCusker, Elizabeth ;
Kirik, Deniz ;
Halliday, Glenda ;
Petersen, Asa .
ACTA NEUROPATHOLOGICA, 2010, 120 (06) :777-788